Santarus competitors

Milind Deshpande is a President and Chief Executive Officer at ACHILLION PHARMACEUTICALS INC and is based in United States.

Mr. Sherman joined Chimerix in 2019 as Chief Executive Officer. Before joining the Company, he served as Chief Executive Officer of Endocyte and led it from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy. He joined the company in 2006 and as Chief Financial Officer and Chief Operating Officer and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Biospecifics Technologies, Inc, and as Chairman of the Board of Trustees for the Children’s Museum of Indianapolis. He also served on the Board of Directors at Mead Johnson Nutrition until the company’s acquisition by Reckitt Benckiser.

An intuitive leader who engenders a deep level of trust and loyalty while providing a clear vision and business strategy, with a proven track record in the pharmaceutical, generic, biotechnology and consumer product industries. Recognized for entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise, all driving shareholder value. Open to contract C-level and Board of Director positions.